# A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

> **NCT07032272** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Autoimmune and Chronic Inflammatory Diseases

## Interventions

- **DRUG:** remibrutinib

## Key facts

- **NCT ID:** NCT07032272
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-23
- **Primary completion:** 2025-10-12
- **Final completion:** 2025-10-14
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07032272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07032272, "A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07032272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*